| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5594379 | American Heart Journal | 2017 | 33 Pages |
Abstract
The VANISH trial is testing a new strategy of disease modification for treating sarcomere mutation carriers with early HCM, and those at risk for its development. In addition, further insight into disease mechanisms, response to therapy, and phenotypic evolution will be gained.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Carolyn Y. MD, John J.V. MD, Allison L. MS, Steven D. MD, Sharlene M. MD, Akshay S. MD, Steven E. MD, Calum A. MD, PhD, Ling MD, Scott D. MD, E. John MD, Eugene Braunwald,